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Threatening the entire world, the 
burden of the COVID-19 pandemic 
has continued to grow, with devastat-
ing effects on human health, social 
connections, and economic liveli-
hoods. These crushing burdens are 
likely to increase dramatically as the 
pandemic continues its relentless 
march across the globe. Some gov-
ernments have taken steps to miti-
gate the worst impacts of this threat 
through aggressive public health 
interventions — including diagnostic 
testing, contact tracing, widespread 
masking, and physical distancing 
— but with the pandemic expected 
to inflict unprecedented human suf-
fering in the months ahead, it has 
become clear that only a vaccine will 
be able to contain the COVID-19 
threat.
There has not been a more sought-
after medical resource in our lifetimes 
than a safe and effective COVID-19 
vaccine, and given this existential 
threat, vaccine candidates will move 
swiftly into clinical trials in the com-
ing months. While vaccine develop-
ment holds great promise, the dis-
covery phase is only the first step. 
Clinical trials may well demonstrate 
that one or more vaccine candidates 
is safe and effective, yet those vac-
cines must still be approved by regu-
latory authorities, manufactured and 
distributed to scale, and made afford-
able for all. Depending on how these 
issues are resolved, a prospective vac-
cine could heal the rifts of a bitterly 
divided world, or it could exacerbate 
them if countries hoard a necessary 
vaccines and undermine equitable 
access.
This column explores the global 
health law reforms necessary to pro-
gressively realize universal access to a 
future COVID-19 vaccine. We begin 
by explaining the importance of 
global health law in the distribution 
of essential vaccines as a determinant 
of public health. The column then 
turns to examine the human rights 
foundations of global health law, con-
ceptualizing vaccination access as a 
universal human right. We find that 
it will be crucial to develop legal com-
mitments to ensure vaccine access 
prior to a scientific breakthrough, 
analyzing the legal barriers that 
impede global access and the global 
health law reforms necessary to facil-
itate global solidarity.
Vaccination Access through 
Global Governance
As governments have found them-
selves constrained in national efforts 
to mitigate the pandemic, it appears 
almost certain that COVID-19 will 
not be controlled globally without the 
development of a vaccine. An effec-
tive vaccine will be essential to limit 
the spread of the SARS-CoV-2 virus, 
prevent it from reoccurring, and bring 
about the eventual containment of the 
COVID-19 pandemic. Without lasting 
protection from infection and popu-
lation-level immunity, the world will 
face higher transmission, repeated 
outbreaks, and unnecessary deaths.1 
Yet, these immunization benefits can 
only be realized if there is sufficient 
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access across all countries. If any coun-
try or region is left out, global protec-
tion remains at considerable risk.
Ensuring worldwide vaccination 
coverage will require global gover-
nance. An effective vaccine should 
be seen as a global public good, 
with benefits shared by all nations 
but requiring global cooperation to 
guarantee its benefits.2 No coun-
try should hoard it. No corporation 
should profit from it. And no insti-
tution or individual should own 
intellectual property rights. Despite 
the rise of “vaccine nationalism,” no 
country acting alone can assure suc-
cess.3 Collaboration and coordination 
are needed for every stage in vaccine 
development and implementation: 
scientific cooperation in discovery 
and clinical trials, global manufac-
turing and distribution in sufficient 
quantities, and equitable allocation 
worldwide. We are unlikely ever 
to eradicate SARS-CoV-2, but the 
World Health Organization (WHO) 
vaccination campaign that eradicated 
smallpox demonstrates the need for 
international cooperation, bringing 
nations together to accomplish what 
none can do alone.
Effective governance for vaccine 
discovery, production, and distri-
bution requires a coalition of state 
and non-state actors through global 
health law. Even if several vaccines 
are approved in the coming year, 
few low- and middle-income coun-
tries (LMICs) will have the capacity 
to produce vaccines without afford-
able access to global supply chains.4 
Determining how to distribute a vac-
cine within and across countries is a 
global concern that cannot be decided 
by a single nation or pharmaceutical 
corporation.5 With so much global 
competition, no government can be 
sure its scientists or pharmaceutical 
companies will be “first and best.” It is 
now, before we know who will prevail 
in this vaccine competition, that we 
must plan for equity.6 Global health 
law reforms are necessary to assure 
that a prospective vaccine is distrib-
uted fairly based upon global norms, 
realizing vaccination as a universal 
right. 
Vaccination as a Human Right
Human rights law provides an inter-
national legal foundation for the pro-
gressive realization of vaccine access. 
COVID-19 not only endangers health 
and longevity, but does so inequitably 
— burdening the poor, the sick, the 
disadvantaged, and the marginalized. 
Recognizing the equal dignity of all 
persons, human rights law requires 
equitable access to essential vaccines 
for disease prevention and health 
promotion.7 A growing anti-vaccina-
tion movement is already mobilizing 
under “rights” discourse to oppose 
a prospective COVID-19 vaccine;8 
however, this co-optation of human 
rights rhetoric does not obviate 
human rights obligations to ensure 
access to essential medicines. In real-
izing the highest attainable standard 
of health through vaccination, human 
rights law provides an international 
obligation to progressively realize the 
prevention, treatment, and control of 
prevalent diseases.
Access to an essential lifesaving 
vaccine is a core human rights obliga-
tion. Immunization is science’s best 
prevention tool and remains a quint-
essentially important element of the 
right to the highest attainable stan-
dard of health.9 The United Nations 
Special Rapporteur on the right to 
health concluded that states are obli-
gated to “do all they reasonably can 
to make sure that existing medicines 
are available in sufficient quanti-
ties.”10 The widespread provision of 
a COVID-19 vaccination also finds 
support under the human right to the 
benefits of scientific progress, requir-
ing that states provide resources for 
the distribution of scientific progress, 
remove discriminatory barriers, and 
ensure access to the “most advanced, 
up-to-date, and verifiable science 
available.”11 In realizing these rights, 
a COVID-19 vaccination, similar to 
life saving antiretrovirals for HIV, 
will almost certainly be classified by 
WHO as an “essential medicine,” rais-
ing national and international obliga-
tions to ensure access.12
States bear international legal 
obligations to progressively real-
ize universal access to vaccines, 
demanding that national resources 
and international assistance move “as 
expeditiously and effectively as pos-
sible towards the full realization” of 
rights.13 To implement human rights 
to a prospective COVID-19 vaccine, 
states must ensure that any safe and 
effective vaccination is:
• Available — requiring that states 
provide sufficient quantities of 
vaccine goods and services and 
highlighting the importance of 
While vaccine development holds great promise, 
the discovery phase is only the first step. Clinical 
trials may well demonstrate that one or more 
vaccine candidates is safe and effective, yet those 
vaccines must still be approved by regulatory 
authorities, manufactured and distributed to 
scale, and made affordable for all. Depending 
on how these issues are resolved, a prospective 
vaccine could heal the rifts of a bitterly divided 
world, or it could exacerbate them if countries 
hoard necessary vaccines and undermine 
equitable access.
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widespread production and rapid 
distribution.
• Accessible — requiring that the 
distribution of vaccines accounts 
for obstacles faced by vulnerable 
and marginalized populations, 
ensuring a vaccine that is afford-
able, within safe physical reach, 
and delivered with all necessary 
information.
• Acceptable — requiring that this 
essential intervention be respect-
ful of medical ethics such as 
informed consent and be designed 
to account for distinct cultural con-
siderations across populations.
• Of Sufficient Quality — requiring 
that the vaccine be “scientifically 
and medically appropriate and of 
good quality,” avoiding counterfeit 
and sub-standard vaccines and 
employing skilled personal and 
approved equipment.14
The implementation of human rights 
to realize access to a COVID-19 vac-
cine will require the development 
of new forms of global governance 
through law. 
Global Governance through 
Global Health Law
The reform of global health law to 
ensure universal access to a COVID-
19 vaccine will require: facilitating 
funding and benefit sharing, easing 
intellectual property protections, 
and harmonizing national vaccine 
regulations.
Funding and Benefit Sharing
Equitable access to a COVID-19 vac-
cine will hinge on its widespread pro-
duction, global supply chains, accessi-
bility, acceptability, and affordability. 
Global governance could lower vac-
cine prices, ramp up industry pro-
duction, and ensure global distri-
bution, but existing Global Public/
Private Partnerships (GPPPs) lack 
the legal accountability necessary to 
ensure benefit sharing. Gavi, the Vac-
cine Alliance was the first GPPP to 
use advanced market commitments 
and bulk purchasing to secure lower 
vaccine prices.15 To accelerate the 
development of new vaccines against 
emerging infectious diseases, the 
Coalition for Epidemic Preparedness 
Innovations (CEPI) was launched to 
facilitate access to new vaccines dur-
ing outbreaks. With both Gavi and 
CEPI repurposing to facilitate access 
to a future COVID-19 vaccine, WHO 
has joined them in establishing a new 
GPPP, the COVID-19 Vaccine Global 
Access (COVAX) Facility; however, 
even with support from large donor 
countries and foundations, these 
GPPPs lack the legitimacy and fund-
ing with which to coordinate nation-
alist governments and pharmaceuti-
cal companies.16
There is a need to create a univer-
sal global health law mechanism to 
ensure equitable benefit sharing, par-
ticularly for LMICs that have limited 
access to new health technologies. 
The WHO Pandemic Influenza Pre-
paredness (PIP) Framework is the 
only existing global mechanism to 
obligate governments to share bio-
logical samples and genetic sequenc-
ing data needed to promote research. 
The PIP Framework also promotes 
equitable sharing of the benefits of 
research. That Framework, how-
ever, only applies to pandemic influ-
enza pathogens.17 Although there 
are a number of GPPPs to promote 
knowledge-sharing in COVID-19 
research,18 a binding framework for 
equitable sharing will be needed to 
prevent states from hoarding a pro-
spective vaccine. New benefit sharing 
agreements in global governance can 
ensure that states act for the common 
good, limit the commercialization of 
publicly funded research, and support 
equitable COVID-19 vaccine access.
Intellectual Property
The tensions between intellectual 
property and public health could 
also impede global access to a pro-
spective COVID-19 vaccine. Under 
World Trade Organization (WTO) 
governance, the Agreement on 
Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) allows for 
the global enforcement of intellec-
tual property (IP) rights. The TRIPS 
agreement thus allows developers of 
vaccines to enforce patent protec-
tions to monopolize production and 
maximize profit.19 As TRIPS made 
life-saving medicines unaffordable in 
LMICs, the 2001 WTO Doha Decla-
ration sought to create “flexibilities” 
to limit IP protections to protect pub-
lic health.20 However, these measures 
to support affordable medicines can-
not easily be translated to vaccines. 
Compulsory licensing can remove IP 
barriers for the production of generic 
medicines, but in the context of vac-
cines, these IP flexibilities cannot 
address the shortage of infrastruc-
ture, capacity, technical knowledge, 
and regulatory recognition necessary 
for generic vaccines.21
Making vaccines affordable 
requires increasing vaccine manu-
facturing capacity in LMIC and 
providing new legal mechanisms to 
share technical production processes. 
Understanding protections on pro-
duction processes — not only final 
products — will be crucial to making 
a COVID-19 vaccine affordable. UNI-
TAID and the Medicines Patent Pool 
have successfully negotiated global 
patent clearing houses to support the 
production of affordable drugs.22 The 
COVID-19 Technology Access Pool 
(C-TAP)  recognizes the complexity 
of making vaccines affordable and 
seeks to facilitate the sharing of data, 
IP, and knowledge while compensat-
ing the patent holder.23 C-TAP could 
play a critical role in making compul-
sory licenses feasible for a COVID-19, 
vaccine but this voluntary system24 
will require stronger enforcement 
through global health law to ensure 
widespread participation of public 
and private actors and alignment of 
international trade law with global 
health imperatives.
Vaccine Regulation
Finally, where the safety and effec-
tiveness of a COVID-19 vaccine will 
require approval in every country, 
creating a patchwork of national reg-
ulatory obstacles, global health law is 
necessary to harmonize and expedite 
national vaccine regulations. In many 
countries, national approval pro-
cesses may be unduly burdensome 
— and at times unnecessary if a strin-
gent regulatory authority (like the 
US FDA or the European Medicines 
Agency) has already approved the 
Gostin, Abdool Karim, and Meier
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technology.25 Simultaneously, a lack 
of regulatory capacity in some coun-
tries can delay rollout or allow falsi-
fied or substandard products to enter 
the market.26 Despite WHO efforts 
to harmonize national approval pro-
cesses, national governments have 
differing regulatory capacities to 
evaluate and approve new drugs, 
and vaccine approval processes have 
remained slower than necessary in 
many countries.27
Against this diverse national regu-
latory landscape, global health law 
can support the regulation of new 
vaccines in an efficient and effective 
manner. The WHO Pre-Qualification 
Process28 (PQP) can serve in place of 
national regulations and streamline 
regulatory approvals for a COVID-
19 vaccine — provided that states 
introduce laws recognizing the PQP. 
WHO has additionally recommended 
the establishment of National Immu-
nization Technical Advisory Groups 
(NITAG) to provide evidence-based 
advice on vaccines and immuniza-
tion.29 NITAGs can support regula-
tions for the financing and delivery 
of prospective vaccines and priori-
tize public health and health equity 
in vaccine access. By strengthening 
national capacity to approve vac-
cines, global health law can support 
efficient processes to regulate and 
approve a safe and effective COVID-
19 vaccine.
Overcoming the World’s Greatest 
Challenge 
The COVID-19 response has proven 
to be the greatest challenge the world 
has faced in generations, and it can 
be contained only if nations are will-
ing and able to work together. Yet, 
despite an imperative for collective 
action, governments have scrambled 
to establish nationalist legal agree-
ments to hoard prospective vaccines 
while dividing the world in ways that 
will prolong the pandemic threat. 
Although the barriers to global health 
coordination and universal vaccine 
access remain complex, global health 
law can support global solidarity in 
facing this common threat, reaching 
agreements now to secure equitable 
access to a hopeful new vaccine. 
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